Registry of Lobbyists
Pfizer Canada ULC
Subject Matter: Retrospective: | Informal communications, phone calls, written communications, meetings, presentations with: ministers, members of parliament, senators, political advisors and civil servants. |
Subject Matter: Prospective: | Informal communications, phone calls, written communications, meetings, presentations with: ministers, members of parliament, senators, political advisors and civil servants. |
Categories | Description |
---|---|
Regulation, Legislative Proposal | Access to Information Act & Regulations |
Regulation | Canadian Access to Medicines Regime (consultations) |
Policy or Program | Canadian Institute of Health Researchers (CIHR) and other Research Oriented Spending Programs |
Policy or Program | Canadian Strategy for Cancer Control |
Policy or Program | Clinical Assessment of Abuse Liability for Drugs with Central Nervous System (CNS) Activity-Draft Guidance |
Policy or Program | Clinical Evaluation of QT/QTc Interval Prolongation & Proarrhythmic Potential for Non-Antarrythmic Drugs-Adoption of International Conference on Harmonization (ICH) Guidelines (Health Canada document: QT/QTc Interval Prolongation: Guidance for Product Monograph Content or see: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/qtqtc/qt_pm_mp_e.html#1) |
Regulation | Clinical Trials Regulations (Division 5) |
Legislative Proposal, Policy or Program | Competition Act Amendments, Competition Bureau Studies |
Grant, Contribution or Other Financial Benefit | Consultation on Scientific Research and Experimental Development (SR&ED) |
Policy or Program | Cost Recovery & Performance |
Policy or Program | Cross Border Trade |
Regulation | Data Protection/Patented Medicines Notice of Compliance Regulations [PM(NOC) Regulations] |
Policy or Program | Department of National Defense Health Benefits Program |
Legislative Proposal | Drug Product Review & Approval System |
Regulation | Drug Product Review & Approval System / Regulations (filing formats of drug submissions, i.e. electronic Common Technical Document (eCTD) providing review tools currently not listed in the regulations) |
Policy or Program | Drug Safety |
Policy or Program | Drugs Review & Approval Systems (Improving the efficiency of over-the-counter and natural health products) |
Policy or Program | Federal/Provincial/Territorial Pharmaceutical Management Initiative: Canadian Agency for Drugs and Technologies in Health (CADTH) |
Policy or Program | Federal/Provincial/Territorial Pharmaceutical Management Initiative: Canadian Expert Drug Advisory Committee (CEDAC) ) |
Policy or Program | Federal/Provincial/Territorial Pharmaceutical Management Initiative: Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) |
Policy or Program | Federal/Provincial/TerritorialPharmaceutical Management Initiative: Common Drug Review (CDR) |
Policy or Program | Federal/Provincial/Territorial Pharmaceutical Management Initiative: National Prescription Drug Utilization Information System (NPDUIS) |
Regulation, Bill or Resolution | Federal Accountability Act |
Policy or Program | Federal Tobacco Control Strategies |
Policy or Program | Food & Drug Act & Regulatory Policies - Good Manufacturing Practices and Establishment Licensing |
Regulation | Food & Drug Regulations (Good Manufacturing Practices & Establishment Licensing) |
Regulation | Food & Drugs Act (Drug Review & Approval regulations, Amendments to FDA, Data protection, Direct-to-Consumer Advertising Regs, New Substance Notification Regulations, Clinical Registry and Disclosure Regulation, GMP & Establishment Licensing) |
Legislative Proposal | Food and Drugs Act (Cross Border Trade [CBT], Drug Export Restrictions, Regulatory Policies) |
Policy or Program | Health Canada Memorandum of Understanding with the US Food and Drugs Administration |
Policy or Program | Health Canada Non-insured Health Benefits Program |
Policy or Program | Health Canada Pharmaceutical and Biological Policies and Applicable Guidelines |
Policy or Program | Health Canada Pharmaceutical Policies and Guidelines |
Policy or Program | Health Canada Probationary / Progressive Licensing Framework |
Policy or Program | Health Canada Site Inspections' program |
Policy or Program | Health Canada Subsequent Entry Biologics Policy |
Policy or Program | Health Canada Therapeutic Access Strategy |
Legislative Proposal | Health Protection Act (Legislative Renewal) |
Policy or Program | Improving the efficiency of the drug review and approval process (Health Canada's Blue Print/Progressive Licensing Framework) |
Policy or Program | Innovation Agenda |
Policy or Program | Intellectual Property Protection |
Policy or Program | Management of Submission Poilcy |
Policy or Program | National Pharmaceutical Strategy |
Legislative Proposal | Patent Act |
Regulation | Patent Act (NoC Linkage) Regulations |
Regulation | Patent Act (Patented Medicines (Notice of Compliance)) Regulations - Amendments to prices review board |
Regulation, Bill or Resolution | Patented Medicine Prices Review Board (PMPRB) Regulations |
Policy or Program | Patent Policies |
Policy or Program | Pharmacogenomics/Biomarkers |
Policy or Program, Regulation | PMPRB (Patented Medicine Prices Review Board) (Appointment policies/guideline changes/regulations) |
Legislative Proposal | Pre-Budget Consultations |
Policy or Program | Proposed Clinical Trials Registry-Disclosure |
Policy or Program | Public Service Health Care Plan |
Policy or Program | Royal Canadian Mounted Police National Health Services |
Policy or Program | Science and Technology Policy |
Policy or Program | Smart Regulations (Specific, measurable, attainable, realistic, timelines Regulations) |
Policy or Program | Veterans Affairs Drug Benefits Plan |
Policy or Program | Veterinary Drug Distribution (VDD) post- NOC (Notice of compliance) Manufacturing changes guidelines |
Legislative Proposal | Veterinary Drug Distribution (VDDs) Document on Antimicrobial Categorization |